Description:
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH
inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who
have received standard therapy
Title
- Brief Title: Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
- Official Title: A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Clinical Trial IDs
- ORG STUDY ID:
LOXO-IDH-20001
- SECONDARY ID:
2020-002830-33
- SECONDARY ID:
I9Y-OX-JDHB
- NCT ID:
NCT04603001
Conditions
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Chronic Myelomonocytic Leukemia (CMML)
- Myeloproliferative Neoplasms (MPNs)
Interventions
Drug | Synonyms | Arms |
---|
LY3410738 | | Cohort 1 |
Purpose
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH
inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who
have received standard therapy
Detailed Description
This study includes 2 parts: dose escalation and dose expansion. The dose escalation will
enroll eligible patients with select IDH-mutant advanced hematologic malignancies. Once the
maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of LY3410738 is
established, the dose expansion will begin and enroll into 4 cohorts to further evaluate
safety and clinical activity
Trial Arms
Name | Type | Description | Interventions |
---|
Dose Escalation Arm A (Monotherapy) | Experimental | Patients not requiring a strong CYP3A4 inhibitor. | |
Dose Escalation Arm B (Monotherapy) | Experimental | Patients requiring a strong CYP3A4 inhibitor for active management or prevention of a lifethreatening condition, such as an azole administered to prevent invasive fungal infection. | |
Cohort 1 | Experimental | Patients with R/R AML harboring an IDH1 R132 mutation who have received a prior IDH inhibitor. | |
Cohort 2 | Experimental | Patients with R/R AML harboring an IDH1 R132 mutation who have not received a prior IDH inhibitor. | |
Cohort 3 | Experimental | Patients with R/R MDS, chronic myelomonocytic leukemia (CMML) or other advanced hematologic malignancy harboring an IDH1 R132 mutation, | |
Cohort 4 | Experimental | Patients with R/R AML, MDS, CMML or other advanced hematologic malignancy harboring IDH2 mutations. | |
Eligibility Criteria
Inclusion Criteria:
- Advanced IDH mutant hematologic malignancy
- Patients must have received prior therapy
- Blasts at least 5% in bone marrow.
- Patients must have a qualifying IDH1 R132, IDH2 R140 or IDH2 R172 mutation
- Eastern Cooperative Oncology Group (ECOG) 0-2
- Adequate organ function
- Ability to swallow capsules or tablets
- Ability to comply with outpatient treatment, laboratory monitoring, and required
clinic visits for the duration of study participation
- Willingness of men and women of reproductive potential to observe conventional and
effective birth control for the duration of treatment and for 3 months following the
last dose of study treatment.
Exclusion Criteria:
- Investigational agent or anticancer therapy within 2 weeks or 5 half-lives, whichever
is shorter; or investigational monoclonal antibody within 4 weeks prior to planned
start of LY3410738
- Major surgery within 4 weeks prior to planned start of LY3410738.
- Active, uncontrolled clinically significant systemic bacterial, viral, fungal or
parasitic infection or an unexplained fever > 38.5ºC during screening or on the first
day of study drug administration.
- Another concurrent malignancy requiring active therapy.
- Active central nervous system involvement
- Any unresolved toxicities from prior therapy greater than CTCAE v5.0 Grade 2 at the
time of starting study treatment except for alopecia.
- History of hematopoietic stem cell transplant (HSCT) or CAR-T therapy within 60 days
of the first dose of LY3410738
- Clinically significant cardiovascular disease
- Active hepatitis B virus (HBV)
- Active hepatitis C virus (HCV)
- Clinically significant active malabsorption syndrome or other condition likely to
affect gastrointestinal (GI) absorption of the study drug
- Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or
inducers and/or P-gp inhibitor, with the exception of patients being treated with
allowed antifungal inhibitors of CYP3A4
- Treatment with proton pump inhibitor (PPIs) within 7 days of starting LY3410738
- Any serious underlying medical or psychiatric condition (e.g. alcohol or drug abuse),
dementia or altered mental status or any issue that would impair the ability of the
patient to understand informed consent or that in the opinion of the investigator
would contraindicate the patient's participation in the study or confound the results
of the study
- Known human immunodeficiency virus (HIV), excluded due to potential drug-drug
interactions between anti-retroviral medications and LY3410738
- Pregnancy, lactation or plan to breastfeeding during the study or within 90 days of
the last dose of study intervention
- Known hypersensitivity to any of the components of LY3410738 or its formulation
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | For Dose Escalation |
Secondary Outcome Measures
Measure: | To determine the safety profile and tolerability of LY3410738 including acute and chronic toxicities by collecting and evaluating adverse events and treatment emergent adverse events |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | For Dose Escalation |
Measure: | To characterize the pharmacokinetics (PK) properties of LY3410738 by collecting and evaluating serum at protocol specified time points |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | For Dose Escalation |
Measure: | To characterize the pharmacodynamic properties of LY3410738 as expressed by change in 2-HG oncometabolite levels in plasma |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | For Dose Escalation |
Measure: | To assess the activity of LY3410738 as measured by the overall response rate (ORR) per investigator assessment |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | For Dose Escalation |
Measure: | To assess the activity of LY3410738 as measured by Best Overall Response per investigator assessment |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | For Dose Expansion |
Measure: | To assess the activity of LY3410738 by Complete Response Rate plus partial hematologic recovery (AML patients) |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | For Dose Expansion |
Measure: | To assess the activity of LY3410738 by Duration of Response |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | For Dose Expansion |
Measure: | To assess the activity of LY3410738 by Hematologic improvement in patients with MDS |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | For Dose Expansion |
Measure: | To determine the safety profile and tolerability of LY3410738 including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | For Dose Expansion |
Measure: | To characterize the pharmacokinetics (PK) properties of LY3410738 by collecting and evaluating serum at protocol specified time points |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | For Dose Expansion |
Measure: | To characterize the pharmacodynamic properties of LY3410738 as expressed by change in 2-HG oncometabolite levels in plasma. |
Time Frame: | Up to 30 months |
Safety Issue: | |
Description: | For Dose Expansion |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Eli Lilly and Company |
Trial Keywords
- Loxo
- LY3410738
- isocitrate dehydrogenase
- IDH
- IDH1
- IDH2
- R132
- R140
- R172
- 2-hydroxyglutarate
- 2-HG
- Advanced Hematologic Malignancies
- Blasts
- Acute Myeloid Leukemia
- AML
- Relapsed/refractory AML
- R/R AML
- Myelodysplastic Syndrome
- MDS
- Chronic Myelomonocytic Leukemia
- CMML
- Myeloproliferative Neoplasms
- MPN
- Advanced Hematologic Cancers
- Ivosidenib
- AG-120
- Vorasidenib
- AG-881
- Olutasidenib
- FT-2102
- BAY1436032
- DS-1001
- IDH-305
- Enasidenib
- AG-221
Last Updated
August 27, 2021